PHYH

PHYH (PAHX) encodes phytanoyl-CoA alpha-hydroxylase, the enzyme that catalyzes the committed alpha-hydroxylation step of peroxisomal phytanic acid alpha-oxidation (PMID:9326939). It is an iron-dependent dioxygenase that uses 2-oxoglutarate as a cosubstrate to alpha-hydroxylate phytanoyl-CoA (PMID:9326939). Catalytic function requires correct subcellular delivery: PHYH carries a type-2 peroxisomal targeting signal (PTS2) and depends on the PTS2 receptor PEX7 for import into peroxisomes, an interaction confirmed by direct binding and by loss of localization in PEX7-deficient cells (PMID:9326939). Inactivating mutations in PHYH cause autosomal recessive Refsum disease, with phytanic acid accumulation as the biochemical hallmark, and the same disorder also arises from PEX7 mutations that abolish PHYH peroxisomal targeting—placing both genes on a single alpha-oxidation axis (PMID:9326939, PMID:14974078).

1. 1997 High

   Established the molecular identity and catalytic mechanism of the enzyme defective in Refsum disease by showing PHYH is an iron- and 2-oxoglutarate-dependent dioxygenase acting on phytanoyl-CoA.

   Evidence in vitro enzymatic assay with cofactor characterization

   PMID:9326939

   Open questions at the time

   • No structural model of the catalytic site reported in the corpus
   • Kinetic regulation of the enzyme not characterized
2. 1997 High

   Resolved how the enzyme reaches its compartment, demonstrating PHYH uses a PTS2 signal and the receptor PEX7 for peroxisomal import.

   Evidence cell-based localization in PEX7-deficient cells plus yeast two-hybrid interaction

   PMID:9326939

   Open questions at the time

   • Stoichiometry and structural basis of the PHYH-PEX7 interaction not defined
   • Cargo release mechanism inside the peroxisome not addressed
3. 1997 High

   Linked the gene to disease by showing homozygous inactivating PHYH mutations cause classic Refsum disease with phytanic acid accumulation.

   Evidence patient mutation analysis with biochemical phenotyping

   PMID:14974078 PMID:9326939

   Open questions at the time

   • Genotype-phenotype relationships across mutation classes not enumerated here
4. 2004 Medium

   Placed PHYH within a genetically heterogeneous disease framework, showing Refsum disease results from disruption of phytanic acid alpha-oxidation by either PHYH or PEX7 mutations.

   Evidence molecular genetic analysis across patients with mechanistic pathway review

   PMID:14974078

   Open questions at the time

   • Relative frequency of PHYH versus PEX7 etiology not quantified here
   • Single consolidating analysis
5. 2024 Medium

   Refined genotype-phenotype understanding by showing a splice-site variant produces in-frame exon skipping and an attenuated disease form, linking partial transcript function to milder phenotype.

   Evidence patient-derived RNA reverse transcription and Oxford Nanopore single-molecule amplicon sequencing

   PMID:38411969

   Open questions at the time

   • Residual enzymatic activity of the skipped-exon protein not measured
   • Single-lab study

• How PHYH catalytic output and import are regulated, and the structural basis of substrate and cofactor engagement, remain open.
• No structural data
• No regulation or post-translational control characterized